Trial 9L-16-13


A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the FLT3 Inhibitor Gilteritinib (ASP2215) Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects with FLT3/ITD AML in First Complete Remission

Type: Treatment
Phase: Phase III
Status: Not Open (Closed)
Treatments: Other
Randomized: Yes
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Mojtaba Akhtari, M.D.
Other Trial Staff:  Ramona Lujan, Coordinator, Grace Facio, Coordinator, Ibrahim Syed, Coordinator, Melissa Peralta, D.M., Jubilee Acap, Coordinator, Laurie De Oliveira, Coordinator, Teresa Olea, Coordinator, Donna Fernando, Coordinator, Meena Ibrahim, D.M., Bartolo Santos, Coordinator, Kseniia Kulakova, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.